Hong Kong’s main innovation incubator together with authorities officers on Thursday restated their long-haul support for cell and gene therapy (CGT) by way of higher coverage and requirements alignments.
Local biomedical lovers expressed their confidence within the worldwide competitiveness of Hong Kong’s CGT sector, with sufferers and medical doctors giving firsthand accounts of remedy and restoration throughout an occasion held on the Hong Kong Science Park, a thriving innovation neighborhood that homes over 2,500 expertise firms working within the fields of synthetic intelligence, robotics, life and well being tech, inexperienced expertise and superior manufacturing.
At the forefront of the healthcare sector, CGT is utilized to switch the expression of a gene or to change cells for remedy. It is at present getting used to deal with sure cancers and genetic illnesses which might be tough to deal with with standard therapies.
The occasion served as a showcase of native enterprises’ CGT achievements and was attended by 200 students and representatives from medical firms.
ALSO READ: Greater Bay Area emerges as launchpad for China’s biotech rise
At the middle of the occasion was town’s first licensed allogeneic mesenchymal stem cell manufacturing plant, which has earned PIC/S GMP (Pharmaceutical Inspection Co-operation Scheme / Good Manufacturing Practice) recognition, a global gold customary for pharmaceutical manufacturing high quality.
Opened by Hong Kong Regen Medtech Ltd in May, the plant can produce superior therapeutic merchandise for medical trials.
Senior executives from over 10 expertise corporations, all based mostly within the park and specializing in superior CGT, detailed their newest medical work and strategic outlook throughout three showcase classes — on gene therapy and rising platforms, on stem cell therapy, and on CAR-T and immunotherapy — earlier than a patient-physician speak.
Welcoming the group, Terry Wong Ping-sau, CEO of Hong Kong Science and Technology Parks Corp, operator of the park, stated Hong Kong holds a “uniquely advantageous position” to drive CGT improvement, because the nation’s fifteenth Five-Year Plan (2026–30) has positioned biomedicine amongst rising pillar industries for future development.
READ MORE: China ‘emerging a global leader’ in biotech business
Wong cited Hong Kong’s aggressive strengths as together with its world-class regulatory requirements, sturdy mental property protections, free commerce insurance policies, and its place as a direct gateway to the huge Chinese mainland market.
Wong reported that over 360 life and well being expertise firms are actually based mostly on the park, working throughout gene therapy, stem cells, and immune oncology.
He additional expressed his hope of seeing CGT designated as a precedence in Hong Kong’s first five-year plan and reaffirmed the park’s dedication to serving to to speed up superior therapy in areas similar to higher manufacturing high quality, larger alignment with world regulatory requirements, and extra environment friendly translation of analysis outcomes into medical purposes.
Andy Wong Wai-cheuk, head of Innovation & Technology and Life & Health Sciences at Invest Hong Kong — a authorities physique overseeing overseas direct funding — additionally took to the stage to say that “Hong Kong is definitely an ideal platform for CGT development”.
Andy Wong attributed Hong Kong’s strengths primarily to a conducive ecosystem: globally top-tier universities main the way in which in life sciences and medication primary analysis, cutting-edge expertise switch services, substantial authorities incentives for commercialization, and a business-friendly local weather strengthened by town’s established standing as a global monetary heart.
READ MORE: HKSTP, five local universities lead record biotech delegation to BIO 2026
He added {that a} “one-stop” regulatory and administrative framework can be below improvement in Hong Kong to support quicker approvals for new medicine and medical gadgets.
In March, Hong Kong’s well being authorities started phasing in a main analysis pathway for the registration of recent medicine. This first part covers purposes for drug merchandise with lively chemical substances which might be already registered in Hong Kong however are actually being submitted for expanded makes use of like new indications, totally different strengths, revised dosage regimes and different formulations.
Under the mechanism, new medicine will be authorized regionally with out ready for clearance from nonlocal regulators. Broader plans embody establishing the Hong Kong Centre for Medical Products Regulation and reaching full main analysis functionality by 2030.
At the occasion, a mom figuring out as Jessica recounted her expertise of receiving in utero maternal haemopoietic stem cell transfusion remedy — led by a analysis group on the Chinese University of Hong Kong — 4 years in the past after studying throughout being pregnant that her fetus had alpha-thalassemia main.
She had additionally been pregnant with an alpha-thalassemia main fetus 10 years earlier however was unable to proceed the being pregnant because the medical expertise obtainable on the time was not sufficiently superior to offer a viable remedy choice.
“A decade on, I found myself confronting the same diagnosis once more. I had already lost hope and thought I could not carry the pregnancy to term,” she stated, “But when I learned that a new CGT treatment was available, I decided to give it a try.”
Jessica gave start safely, and her baby efficiently obtained a stem cell transplant at 2 years outdated.
“I’m deeply grateful for such a new treatment option,” she stated.
Contact the author at [email protected]